VCYT

Veracyte, Inc.

$24.33

-1.22%
Nov 13, 2026
Bobby Quantitative Model
Veracyte, Inc. is a genomic diagnostics company that develops and commercializes molecular tests designed to help clinicians diagnose and treat cancer at pivotal decision points, with a portfolio spanning thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), and bladder cancer (Decipher Bladder), alongside a smaller biopharmaceutical services business. The company occupies a differentiated niche in the diagnostics and research sector, positioning itself as a specialized genomic-testing platform rather than a broad laboratory operator, with roughly 755 employees and a market capitalization near $3.3 billion. The current investor narrative is dominated by a violent post-earnings repricing: despite reporting Q3 2026 revenue of $151.8 million (up 15.1% year over year) and net income of $31.5 million, the stock collapsed roughly 54% in a single session on November 5, 2026, suggesting the market reacted to guidance, reimbursement, or competitive concerns rather than the reported quarter itself. This drawdown has collided with a broader debate over whether the selloff is an overreaction to a fundamentally sound, cash-generative diagnostics franchise or a signal of deteriorating growth durability in an increasingly crowded molecular-testing landscape where rivals such as Natera are expanding internationally.

People also watch

Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc.

TMO

Analysis
Danaher Corporation

Danaher Corporation

DHR

Analysis
Natera

Natera

NTRA

Analysis
IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc.

IDXX

Analysis
Agilent Technologies

Agilent Technologies

A

Analysis

BobbyInvestment Opinion: Should I buy VCYT Today?

Rating: Hold, with a speculative accumulation bias only for risk-tolerant investors. The core thesis is that Veracyte's operating business remains intact — Q3 2026 revenue of $151.75 million grew 15.08% year over year, net income reached $31.50 million, and trailing free cash flow of $161.41 million funds growth internally with debt-to-equity of just 0.030 — yet the 54% single-session collapse on November 5 and a fresh Leerink downgrade to Market Perform mean the market is pricing in a fundamental deterioration that management has not yet quantified. The 9 Buy / 3 Hold / 0 Sell consensus and $57.40 average target imply +137.6% upside, but that target is almost certainly stale and should be discounted until post-collapse revisions are published.

Supporting evidence for not abandoning the name: the forward PE of 13.21x against consensus 2027 EPS of $2.38 is cheap for a profitable diagnostics franchise, and the PEG of 0.31 is among the lowest in the sector. Revenue has climbed sequentially from $139.07 million in Q1 to $150.32 million in Q2 to $151.75 million in Q3, and the company has now posted four consecutive profitable quarters after a $0.98 million loss in Q2 2025. Q3 alone generated $37.92 million of free cash flow on just $2.33 million of capex, and the current ratio of 8.15 with $201.47 million in cash even after $153.19 million of acquisitions confirms solvency is not the issue. The PS ratio of 6.40x and EV/Sales of 2.78x sit far below the 15x-25x PS band the stock held during 2024-2025.

Risks that could invalidate the thesis: gross margin has eroded from 72.32% in Q1 to 70.58% in Q3 (roughly 170 basis points), testing revenue is 96.5% of the total, and Natera's Signatera Japan PMDA bladder-cancer CDx approval in September 2026 signals direct international competition into Decipher Bladder. This Hold would upgrade to Buy if post-collapse analyst revisions stabilize the average target above $35 and management clarifies that the November 5 selloff was sentiment rather than reimbursement or guidance driven; it would downgrade to Sell if 2027 revenue guidance lands below the $945.7 million consensus or gross margin breaks below 70%. On balance the stock looks undervalued relative to its own history and forward earnings, but fairly-to-richly valued on EV/EBITDA of 33.31x and price-to-cash-flow of 24.27x — a genuine value opportunity only if the growth durability question resolves favorably.

Sign up to view all

VCYT 12-Month Price Forecast

The evidence is genuinely two-sided: the operating franchise is healthy — 15.08% revenue growth, 70.58% gross margin, negligible 0.030 debt-to-equity, and $161.41 million in trailing free cash flow — while the market has repriced the stock by more than half in a single session, leaving it at 13.21x forward earnings and 6.40x sales versus a historical 15x-25x PS band. That combination argues the selloff has overshot on valuation, but the accelerating decline (-44.02% in one month, worse than the -42.05% one-year figure) and the Leerink downgrade argue the market knows something the reported quarter does not show. The single factor that would most change the stance is post-collapse analyst revisions: if targets stabilize near $35 or above and management clarifies the November 5 catalyst as sentiment rather than reimbursement or guidance, the stance upgrades to bullish; if 2027 guidance lands below the $945.7 million consensus or gross margin breaks 70%, it downgrades to bearish. With a 55% base-case probability centered on a $35-$45 range, the risk/reward is modestly favorable but not compelling enough to justify high conviction before the next earnings call.

Historical Price
Current Price $24.33
Average Target $24.33
High Target $27.98
Low Target $20.68

Wall Street consensus

Coverage is solid for a mid-cap diagnostics name, with 10 analysts contributing to a consensus that leans clearly bullish: 9 Buy ratings, 3 Hold ratings, and 0 Sells, yielding a recommendation mean of 1.67 (Buy). The average target price of $57.40 implies a staggering +137.6% upside from the current $24.16 — a gap so wide it signals the analyst community has not yet caught up to the November 5 collapse, or believes it is a gross overreaction. Consensus 2027 revenue estimates of $945.7 million and EPS of $2.38 underpin that optimism, but the disconnect between a $57.40 target and a $24.16 price is a red flag for stale coverage that will likely be revised downward in coming weeks. The target range of $35.00 to $70.00 is extremely wide — a 100% spread from low to high — signaling high uncertainty and weak conviction. The high target of $70.00 assumes multiple expansion and accelerating test adoption across the prostate, thyroid, and bladder franchises, while even the low target of $35.00 sits 44.9% above the current price, meaning no analyst currently models the stock at today's level. Recent institutional actions show early cracks: Leerink Partners downgraded to Market Perform from Outperform on November 5, 2026, the same day as the collapse, while Needham maintained Buy and Morgan Stanley held Underweight. The pattern of a fresh downgrade alongside maintained bullish ratings suggests the consensus is in transition, and investors should treat the current average target with skepticism until post-collapse revisions are published.

Drowning in data?

Find the real signal!

Bulls vs Bears: VCYT Investment Factors

The bear case currently has stronger near-term evidence: a 54% single-day collapse, a stock pinned at 5.8% of its 52-week range, accelerating declines (-44% in one month), and a fresh Leerink downgrade all point to a fundamental re-rating rather than a routine pullback, and the $57.40 analyst target is almost certainly stale. The bull case rests on genuinely strong operating data — 15.08% revenue growth, four consecutive profitable quarters, $161.41 million in trailing free cash flow, negligible debt, and a 13.21x forward PE with a 0.31 PEG — which suggests the business itself is not broken. The single most important tension is whether the November 5 collapse reflects a temporary sentiment shock to an intact franchise or the market's early read on reimbursement or competitive deterioration that will show up in 2027 guidance; how that resolves will determine whether 13x forward earnings is a bargain or a value trap. Until post-collapse analyst revisions and management clarification arrive, the evidence favors caution despite the attractive headline multiples.

Bullish

  • Forward PE of 13.2x is remarkably cheap: At $24.16, VCYT trades at just 13.21x forward EPS of $2.38 versus a trailing PE of 50.12x, implying the market expects earnings to roughly quadruple. The PEG ratio of 0.31 is among the lowest in profitable diagnostics, suggesting the selloff has overshot the earnings growth trajectory.
  • Revenue still growing 15% with profits inflecting: Q3 2026 revenue of $151.75 million rose 15.08% year over year from $131.87 million, extending a steady climb from $139.07 million in Q1. Net income of $31.50 million on a 70.58% gross margin marks the fourth consecutive profitable quarter after a $0.98 million loss in Q2 2025.
  • Fortress balance sheet with heavy free cash flow: Debt-to-equity is a negligible 0.030 and the current ratio is 8.15, with $201.47 million in cash even after deploying $153.19 million on acquisitions. Trailing free cash flow of $161.41 million dwarfs reported net income, and Q3 alone generated $37.92 million of FCF on just $2.33 million of capex.
  • Analyst consensus still firmly Buy at $57.40: Nine of ten covering analysts rate VCYT Buy with zero Sells and a recommendation mean of 1.67, and the average target of $57.40 implies +137.6% upside. Even the lowest target of $35.00 sits 44.9% above the current price, meaning no analyst models the stock at today's level.

Bearish

  • 54% single-session collapse signals real problem: The stock fell from a $52.52 close on November 4 to $24.00 on November 5, a roughly 54% one-day wipeout despite a 15.1% revenue beat-and-raise quarter. Markets rarely reprice a stock by half on a clean quarter, implying guidance, reimbursement, or competitive concerns that the reported numbers do not capture.
  • Falling knife pinned at 52-week low: At $24.16, VCYT sits at just 5.8% of its $21.91-$60.91 annual range, with a maximum drawdown of -60.32%. The 1-month change of -44.02% and 3-month change of -48.84% are worse than the -42.05% one-year figure, meaning the decline is accelerating rather than stabilizing.
  • Analyst targets are stale and likely to be cut: The $57.40 average target versus a $24.16 price is a 137.6% gap that almost certainly reflects pre-collapse estimates, and the $35-$70 range is a 100% spread signaling weak conviction. Leerink Partners downgraded to Market Perform on November 5, the same day as the collapse, while Morgan Stanley holds Underweight — the consensus is in transition.
  • Gross margin drifting lower under cost pressure: Gross margin has slipped from 72.32% in Q1 2026 to 72.21% in Q2 to 70.58% in Q3, a roughly 170 basis point decline over two quarters. Combined with operating margin of 14.34% and net margin of 12.83%, this hints at mild cost-of-revenue pressure that could compress profitability if reimbursement tightens.

VCYT Technical Analysis

The prevailing trend is a severe, sustained downtrend that has overwhelmed what had been a strong first-half advance. VCYT is down 42.05% over the trailing year and 43.01% year-to-date, and at $24.16 it sits at just 5.8% of its 52-week range of $21.91 to $60.91 — effectively pinned near the absolute low. This positioning is the hallmark of a falling-knife setup rather than a value opportunity: the stock has surrendered nearly all of its 2026 gains and is testing the floor of its annual range, with a maximum drawdown of -60.32% underscoring how punishing the reversal has been. Momentum has decisively decelerated and then broken. The 1-month change of -44.02% and 3-month change of -48.84% are both dramatically worse than the already-negative 1-year figure, meaning the decline is accelerating rather than stabilizing — the short-term trend is diverging bearishly from the longer-term trend, which typically signals capitulation or a fundamental re-rating rather than a routine pullback. Relative strength confirms the damage: VCYT has underperformed SPY by 39.03 percentage points over one month and 51.64 points over one year, while SPY itself was only down 4.99% in the past month, so this is idiosyncratic, company-specific selling pressure. Volume of roughly 6.58 million shares on the latest session reflects heavy turnover consistent with the post-earnings exodus. Key levels are now starkly defined. Support rests at the 52-week low of $21.91, only about 9.3% below the current $24.16 — a break there would signal a fresh leg lower with little technical cushion. Resistance is anchored at the 52-week high of $60.91, but the more relevant near-term barrier is the pre-collapse level around $52.52 (the November 4 close), which now represents a massive gap that would require a fundamental catalyst to reclaim. With a beta of 1.96, VCYT is nearly twice as volatile as the market, meaning position sizing must account for roughly double the index's price swings — a critical risk-management consideration when the stock is already in freefall.

Beta

—

—

Max Drawdown

-60.3%

Largest decline past year

52-Week Range

—

Price range past year

Annual Return

-39.0%

Cumulative gain past year

PeriodVCYT ReturnS&P 500
1m-44.1%-2.0%
3m-41.0%-2.8%
6m-36.8%+2.1%
1y-39.0%+12.3%
ytd-42.6%+10.6%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

VCYT Fundamental Analysis

The revenue trajectory remains genuinely healthy even as the stock price collapses, creating a sharp disconnect between operating performance and market sentiment. Q3 2026 revenue of $151.75 million grew 15.08% year over year from $131.87 million, extending a steady multi-quarter climb from $139.07 million in Q1 2026 and $150.32 million in Q2 2026. The business is overwhelmingly driven by testing revenue of $146.42 million, with product revenue of just $4.63 million and biopharmaceutical/other at $0.71 million — meaning the investment case hinges almost entirely on continued adoption of the Afirma, Decipher, and Prosigna test franchises. Growth is solid but not accelerating, and the market's harsh reaction implies investors fear deceleration ahead, likely tied to reimbursement pressure or competitive encroachment. Profitability has inflected meaningfully upward. Q3 2026 net income reached $31.50 million on a 70.58% gross margin, up from just $19.14 million in the year-ago quarter, and the company has now posted four consecutive profitable quarters after a loss of $0.98 million in Q2 2025. Operating margin of 14.34% and a net margin of 12.83% reflect a business that has crossed into durable profitability, though gross margin has drifted modestly lower from 72.21% in Q2 2026 and 72.32% in Q1 2026, hinting at mild cost-of-revenue pressure worth monitoring. The balance sheet is a genuine strength. Debt-to-equity is a negligible 0.030, the current ratio stands at an exceptionally liquid 8.15, and trailing free cash flow of $161.41 million dwarfs reported net income, reflecting strong cash conversion. Q3 operating cash flow of $40.26 million against capital expenditures of just $2.33 million produced $37.92 million of free cash flow, and the company holds $201.47 million in cash even after deploying $153.19 million on acquisitions during the quarter. ROE of 5.07% and ROA of 3.72% are modest but positive, and with essentially no leverage, Veracyte funds its growth internally — the financial risk here is valuation and sentiment, not solvency.

Quarterly Revenue

$151754000.0B

2026-09

Revenue YoY Growth

+15.1%

YoY Comparison

Gross Margin

70.6%

Latest Quarter

Free Cash Flow

$161414000.0B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Biopharmaceutical And Other
Product
Testing

Open an Account, get $2 TSLA now!

Valuation Analysis: Is VCYT Overvalued?

Because Veracyte is profitable (Q3 2026 net income of $31.50 million), the PE ratio is the appropriate primary metric. The trailing PE of 50.12x looks rich in isolation, but the forward PE of 13.21x tells a far more compelling story — the gap implies the market expects earnings to roughly quadruple, consistent with consensus EPS estimates of $2.38 versus the trailing $0.02 figure (which is distorted by prior-year losses in the trailing calculation). That enormous trailing-to-forward compression suggests the stock may be materially cheaper on a forward basis than the headline multiple implies. On peer comparison, the picture is mixed and depends heavily on the metric chosen. The PS ratio of 6.40x and EV/Sales of 2.78x are moderate for a profitable, high-growth diagnostics company, while the EV/EBITDA of 33.31x and price-to-cash-flow of 24.27x reflect a premium consistent with the sector's growth expectations. The PEG ratio of 0.31 is strikingly low, suggesting the stock is inexpensive relative to its expected earnings growth — a signal that either the growth estimates are too optimistic or the selloff has overshot. Against its own history, valuation has compressed dramatically. The PS ratio has fallen from 24.42x at Q3 2026 reporting to the current 6.40x, and the PE has dropped from 45.88x in Q2 2026 to 50.12x trailing but just 13.21x forward — placing the stock near the bottom of its multi-year valuation band. Historically VCYT traded at PS ratios in the 15x-25x range during 2024-2025, so the current 6.40x represents a deep discount that could reflect either a compelling value opportunity or the market pricing in genuine fundamental deterioration.

PE

50.1x

Latest Quarter

vs. Historical

Low-End

5-Year PE Range 20x~141x

vs. Industry Avg

35.2x

Industry PE ~35.2x*

EV/EBITDA

33.3x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks center on margin trajectory and revenue concentration rather than solvency. Gross margin has declined from 72.32% in Q1 2026 to 70.58% in Q3, a roughly 170 basis point erosion that, if sustained, would pressure the 14.34% operating margin and 12.83% net margin that underpin the forward earnings story. Testing revenue of $146.42 million represents about 96.5% of the $151.75 million quarterly total, so the entire thesis hinges on continued adoption of Afirma, Decipher, and Prosigna, and any reimbursement cut or volume slowdown in a single franchise would hit results disproportionately. The $153.19 million of acquisitions deployed in Q3 also introduces integration and impairment risk, and the trailing PE of 50.12x versus forward 13.21x means the stock depends on earnings roughly quadrupling to $2.38 — a demanding bar that leaves little room for execution error.

Market and competitive risks are elevated by the stock's extreme volatility and a crowded molecular-testing landscape. Beta of 1.96 means VCYT swings nearly twice the market, and the stock has underperformed SPY by 39.03 percentage points over one month and 51.64 points over one year while SPY itself fell only 4.99% in the past month — this is idiosyncratic, company-specific selling pressure. Natera's Signatera winning Japan PMDA approval as a bladder cancer CDx in September 2026 signals international expansion by a better-capitalized rival directly into VCYT's Decipher Bladder market, and the 54% November 5 collapse suggests investors fear reimbursement pressure or competitive encroachment that management has not yet quantified. The $35-$70 analyst target spread (a 100% range) and Leerink's November 5 downgrade to Market Perform confirm that conviction is weak and coverage is in flux.

The worst-case scenario is a chain in which post-collapse analyst revisions cut targets toward the $35 low, 2027 revenue guidance disappoints on reimbursement or Natera competition, and the forward EPS estimate of $2.38 proves unreachable, forcing the forward PE to re-rate upward toward 20x-25x on lower earnings. In that path, the stock would retest and likely break its 52-week low of $21.91, only 9.3% below the current $24.16, opening a fresh leg lower with little technical cushion; a move to the $18-$20 range would represent roughly -17% to -25% from today. The historical maximum drawdown of -60.32% shows how far this name can fall in a single cycle, and with a short ratio of 6.64, short sellers remain heavily positioned to press any weakness.

FAQ

The most severe risk is company-specific and already visible: a 54% single-session collapse on November 5 despite a clean 15.08% growth quarter, with the stock at just 5.8% of its 52-week range and a -60.32% max drawdown, signaling the market sees a fundamental problem management has not quantified. Second is competitive risk: Natera's Signatera won Japan PMDA approval as a bladder cancer CDx in September 2026, directly encroaching on the Decipher Bladder franchise, while testing revenue of $146.42 million is roughly 96.5% of the $151.75 million total, leaving little diversification. Third is margin and earnings-execution risk: gross margin has slipped from 72.32% in Q1 to 70.58% in Q3, and the forward PE of 13.21x depends on EPS reaching $2.38, so any reimbursement pressure that compresses margins would force a painful re-rating. Fourth is market and sentiment risk: beta of 1.96 nearly doubles index moves, relative strength versus SPY is -39.03 points over one month, and a short ratio of 6.64 means short sellers are positioned to press any weakness toward the $21.91 low.

The 12-month forecast splits into three scenarios with a 55% base case, 25% bear case, and 20% bull case. The base case targets $35-$45, assuming the stock bases near $24.16, analyst targets are cut toward the $35 low end, 2027 revenue lands slightly below the $945.7 million consensus, and the 13.21x forward PE proves a floor. The bear case targets $18-$21.91 on a break of the 52-week low, driven by 2027 guidance disappointment, gross margin falling below 70%, or cascading downgrades beyond Leerink's November 5 move. The bull case targets $57.40-$70.00, requiring management to clarify that reimbursement and guidance are intact, analyst targets to hold near the $57.40 average, and the forward multiple to re-rate toward the 20x-25x band the stock historically commanded. The base case is most likely because the operating franchise remains intact — 15.08% growth, 70.58% gross margin, $161.41 million trailing free cash flow — while the stale $57.40 target and the accelerating -44.02% one-month decline both argue for a period of consolidation rather than an immediate V-shaped recovery.

The answer depends heavily on which multiple you weight, and the dispersion is unusually wide. On forward earnings the stock looks undervalued: 13.21x forward EPS of $2.38 against a trailing PE of 50.12x implies the market expects earnings to roughly quadruple, and the PEG of 0.31 is among the lowest in profitable diagnostics. On sales the compression is dramatic — PS has fallen from 24.42x at Q3 reporting to 6.40x, and EV/Sales of 2.78x is moderate for a 15.08% grower, well below the 15x-25x PS band the stock held during 2024-2025. But on cash-flow and EBITDA metrics the stock still carries a premium: EV/EBITDA of 33.31x and price-to-cash-flow of 24.27x are not cheap, and PB of 2.53x reflects a business with substantial intangible assets from $153.19 million of acquisitions. The market is effectively pricing in either a durable earnings inflection to $2.38 or a growth deceleration that makes today's cash-flow multiples look expensive; the valuation verdict is undervalued relative to its own history and forward earnings, but only fairly valued on EV/EBITDA.

On a risk/reward basis the setup is asymmetric but unresolved. The upside case is anchored by the $57.40 average analyst target, which implies +137.6% from $24.16, and even the lowest target of $35.00 sits 44.9% above the current price; the downside is a retest of the $21.91 52-week low, only about 9.3% below today, with a bear-case range of $18-$21.91 implying roughly -9% to -25%. That skew looks favorable, but the 54% single-session collapse on November 5 and the fresh Leerink downgrade to Market Perform mean the market may be pricing deterioration not yet visible in the reported quarter. The stock is cheap at 13.21x forward EPS of $2.38 and 6.40x sales, with $161.41 million in trailing free cash flow and negligible leverage supporting the balance sheet. It is a reasonable buy only for risk-tolerant investors who size positions for a beta of 1.96 and can wait for management to clarify 2027 guidance; conservative investors should wait for post-collapse analyst revisions before committing capital.

VCYT is structurally a long-term holding but tactically a poor short-term trade right now. The long-term case rests on a profitable, debt-light diagnostics platform — debt-to-equity of 0.030, current ratio of 8.15, $201.47 million in cash, and $161.41 million in trailing free cash flow — growing revenue 15.08% with four consecutive profitable quarters, which supports a multi-year thesis around Afirma, Decipher Prostate, and Prosigna adoption. The short-term case is unattractive because the stock is in freefall: -44.02% over one month, -48.84% over three months, and -42.05% over one year, with beta of 1.96 and a 6.64 short ratio that amplify volatility around any headline. There is no dividend (yield of 0%, payout ratio of 0) to compensate for waiting, so returns depend entirely on price appreciation. A concrete minimum holding period of 12-18 months is appropriate, spanning at least two earnings cycles so that 2027 guidance and post-collapse analyst revisions can resolve the current valuation debate; short-term traders should wait for a confirmed base above the $21.91 low before considering entries.